View printer-friendly version

ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce the appointment of Dr Philip Currie to its Scientific Advisory Board.

“I am delighted that Dr Currie is joining our Scientific Advisory Board,” said Tony Keating, CEO and Managing Director of ResApp Health. “His extensive experience in medical research at leading US hospitals will provide us with invaluable clinical expertise as we move forward with paediatric and adult clinical studies this US winter.”

Dr Currie is a cardiologist with more than 35 years in cardiology both in the United States and in Australia with extensive experience in medical research, clinical cardiology and business. Dr Currie completed his medical residency and cardiology fellowship at the Alfred Hospital in Melbourne, followed by cardiology fellowship and staff cardiologist appointment at the Mayo Clinic. Dr Currie was a staff cardiologist for three years at the Cleveland Clinic and then Director of Echocardiography at the Michigan Heart and Vascular Institute for eight years. Dr Currie has been a Principal Investigator on multiple clinical studies at the Alfred Hospital, the Mayo Clinic and the Cleveland Clinic and was a co-investigator on the high-profile multi-centre international clinical trials, CAPRICORN and SERVE-HF. He received his medical degree from Monash University and holds an
MBA from the University of Michigan.

ResApp further advises that its CEO and Managing Director, Tony Keating, will be in the US later this week to meet with the SMARTCOUGH-C principal investigators.

About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use cough sounds to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation. ResApp has adult and paediatric clinical studies underway at leading US and Australian hospitals with results demonstrating accurate diagnosis of pneumonia, asthma/reactive airways disease, bronchiolitis, croup and upper respiratory tract infections in children as well as chronic obstructive pulmonary disease, asthma, pneumonia and upper respiratory tract infections in adults. Potential customers of ResApp’s products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as global aid and humanitarian organisations in the developing world.

For more information on ResApp, visit www.resapphealth.com.au

Contacts
Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Brian Leedman
VP, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

ResApp Logo White

ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000

LEGAL
Terms of Use
Privacy Policy

ResAppDx-US is pending review of a request for De Novo classification and is not available for sale in the United States.

© 2019 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries.